Three quiet changes to how the UK regulates medicines and devices
What happened
On 1 September 2026, the Medicines and Healthcare products Regulatory Agency announced that the government has tabled three amendments to the Health Bill currently going through Parliament. The MHRA is the body that decides whether medicines and medical devices can be sold and used in the UK, and that watches them for problems afterwards. It is not a household name, but almost every medicine in your cupboard has passed through it. The first amendment is about information sharing. It would give the MHRA clearer legal authority to share specific information about medicines and devices with other UK government bodies and with regulators in other countries. The MHRA says existing protections stay in place, and that commercially sensitive information and patient data remain covered by data protection law and consent rules. The second is about keeping rules up to date. At the moment, when an international technical standard changes, UK law can take a long time to catch up. The amendment would let legislation reflect those updates more automatically. Minor and technical changes could go ahead unless Parliament objects, while significant policy changes would still get full public consultation. The third is the biggest in the long run. It would amend the Medicines and Medical Devices Act 2021 to create the legal basis for a possible future licensing system for medical devices. Today, most devices reach the Great Britain market through assessment by an approved third-party organisation. A licensing system would mean the MHRA itself issuing licences, with the level of scrutiny matched to how risky the device is. The MHRA was careful to state that none of this changes anything immediately, and that any measures agreed would need further development and consultation before being implemented.
Why this matters
Regulation is invisible until it fails. Medical devices cover a huge range of things: hip replacements, insulin pumps, blood glucose monitors, pacemakers, surgical mesh, and increasingly software that reads scans or helps make decisions. They are held to different rules from medicines, and historically those rules have been lighter. The UK has learned this the hard way. The Independent Medicines and Medical Devices Safety Review, published on 8 July 2020 and led by Baroness Julia Cumberlege, examined serious harm linked to surgical mesh, the hormone pregnancy test Primodos and the epilepsy medicine sodium valproate. It described the healthcare system as "disjointed, siloed, unresponsive and defensive" towards the patients affected, and made nine strategic recommendations. The third amendment is a response to that broad direction of travel. Moving from third-party assessment towards licensing by the regulator would mean more direct oversight of devices before they reach patients. The information-sharing change matters for a different reason. Safety signals often show up in one country before another. A regulator that can share and receive information quickly can act sooner. And the technical standards change is really about time. If it takes two years for UK law to reflect an updated safety standard, patients spend two years covered by the old one.
What the evidence actually says
This is a story about intentions, not outcomes, and it is important to keep the two apart. Nothing has changed yet. These are amendments tabled to a bill that is still going through Parliament. They have not been agreed. The MHRA's own statement says the proposals "do not introduce immediate changes to the regulation of medicines or medical devices". The device licensing amendment is even further off. It would create the legal power to build a licensing framework in future. It does not build one. Doing that would need more design work and more consultation. There are reasonable arguments on both sides. Supporters of tighter device rules point to past harms and to the growing complexity of devices, especially software-based ones. Others worry that a licensing system could slow down access to useful technology, or add costs that smaller manufacturers cannot bear. Both concerns are legitimate, and how the system is designed will decide which one turns out to matter more. On the point about minor changes proceeding "unless Parliament objects", it is fair to note the trade-off openly. That approach makes updates faster. It also reduces the amount of debate each change receives. The MHRA's position is that full consultation is preserved for significant policy changes, and that the fast route is for technical matters. We will not know how any of this works in practice for some time.
Practical advice
There is nothing you need to do differently today. But there are habits worth having around medicines and devices. If you think a medicine or a medical device has caused you a side effect or a problem, report it through the MHRA's Yellow Card scheme. You do not need to be certain, and you do not need to be a healthcare professional. Reports from patients are a genuine part of how safety problems get spotted. Keep the patient information leaflet that comes with your medicines, or know where to find it online. It lists side effects and interactions in plain language. If you use a device at home such as a blood glucose monitor, a blood pressure machine or a nebuliser, keep a note of the make and model. If a safety notice is issued, that is the first thing you will be asked for. Be cautious about medical devices bought from overseas websites. A device sold legally in one country may not meet UK requirements, and if something goes wrong, you may have little recourse. If you are ever unsure whether a device or medicine you have is affected by a recall, a pharmacist can check.
What to know
On 1 September 2026 the government tabled three MHRA-related amendments to the Health Bill. One would make it easier for the MHRA to share medicines and device information with other UK bodies and international regulators, while keeping existing data protections. One would let UK law keep pace with updated international technical standards more quickly, with minor changes proceeding unless Parliament objects and full consultation retained for significant policy changes. One would create the legal basis for a possible future system in which the MHRA licenses medical devices directly, rather than relying only on third-party conformity assessment. None of this takes effect now. The amendments must pass through Parliament, and the device licensing power would need further consultation before any system was built. For patients, the most useful thing remains reporting problems through the Yellow Card scheme, which feeds directly into how these decisions get made. Sources: GOV.UK / MHRA, "MHRA regulatory reform amendments tabled in Government's Health Bill", 1 September 2026, https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill | Independent Medicines and Medical Devices Safety Review, "First Do No Harm", 8 July 2020, https://www.immdsreview.org.uk/ | House of Commons Library, "The Independent Medicines and Medical Devices Safety Review", https://commonslibrary.parliament.uk/research-briefings/cbp-9274/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Do not stop or change any medicine or stop using a medical device because of something you have read here.
Related articles
Four hours of training and an AI: heart scans by non-experts show promise
Researchers at the Mayo Clinic have tested a way of using artificial intelligence to help people with no ultrasound experience take useful pictures of the heart…
Your night-time cough may warn of a flu wave a week early, UKHSA study finds
On 3 September 2026, the UK Health Security Agency published the results of a study it carried out with Sleep Cycle, a Swedish company that makes a popular slee…